Serious adverse events · people with moderate to severe Crohn's disease in remission
Ustekinumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · adults with metastatic extradural spinal cord compression (without peptic ulceration or infection; mixed prognosis)
High‐dose corticosteroids probably leads to higher serious adverse events compared with moderate‐dose or no corticosteroids (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with moderately to severely active ulcerative colitis
Vedolizumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events ‐ total · individuals with moderate to severe disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in serious adverse events ‐ total compared with placebo or standard care alone (moderate certainty).
1 finding from 1 review
Serious adverse events by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Bamlanivimab showed no clear difference in serious adverse events by day 30 compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause serious adverse events · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
Tiotropium leads to lower all‐cause serious adverse events compared with ipratropium (high certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events at longest · hospitalised adults with COVID‐19 (moderate to severe disease)
The intervention showed no clear difference in serious adverse events at longest (low certainty).
1 finding from 1 review
Serious adverse events (by day 28) · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in serious adverse events (by day 28) compared with saline placebo (low certainty).
1 finding from 1 review
Serious adverse events ‐ not reported · individuals with moderate to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events at up to day 28 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Remdesivir and standard care showed no clear difference in serious adverse events at up to day 28 compared with standard care (plus/minus placebo) (low certainty).
1 finding from 1 review
Short‐term serious adverse events (SAEs) · adults undergoing intra‐ and transperitoneal laparoscopic procedures
It is very uncertain whether summary of findings table ‐ Deep neuromuscular blockade (NMB) changes short‐term serious adverse events (SAEs) compared with moderate NMB (very low certainty).
1 finding from 1 review
Intervention not reported
Number of people with serious adverse events · people with dementia and mild to moderate pain
1 finding from 1 review
Intervention not reported
Serious adverse events during the trial period · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
It is very uncertain whether the intervention changes serious adverse events during the trial period (very low certainty).
1 finding from 1 review
Serious adverse events during the study period · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in serious adverse events during the study period compared with placebo or standard of care alone (moderate certainty).
1 finding from 1 review
Serious adverse events (SAEs) start of surgery until 8 hours after surgery · adults undergoing intra‐ and transperitoneal laparoscopic procedures
It is very uncertain whether summary of findings table ‐ Deep neuromuscular blockade (NMB) changes serious adverse events (SAEs) start of surgery until 8 hours after… compared with moderate NMB (very low certainty).
1 finding from 1 review
Proportion of participants with one or more serious adverse events due to any cause · children and adults with predominantly mild to moderate asthma
Summary of findings table ‐ Vitamin D showed no clear difference in proportion of participants with one or more serious adverse events… compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events up to day 28 (data available only as a composite of serious adverse events or death up to day 28) · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma showed no clear difference in serious adverse events up to day 28 (data available only as a… compared with saline placebo (low certainty).
1 finding from 1 review
RR 0.72 [0.45, 1.14]
Studies not reported
Low
Serious adverse events "Defined as events that result in death, hospitalization, prolongation of hospitalization, or are life threatening (based on the judgment of the study physician)" (Quinn 2010) · Apathy in people with mild‐to‐moderate Alzheimer's disease
Omega‐3 PUFA supplements showed no clear difference in serious adverse events "Defined as events that result in death,… compared with placebo (high certainty).
1 finding from 1 review